...
首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >Development of a pharmaceutical cocrystal with solution crystallization technology: Preparation, characterization, and evaluation of myricetin-proline cocrystals
【24h】

Development of a pharmaceutical cocrystal with solution crystallization technology: Preparation, characterization, and evaluation of myricetin-proline cocrystals

机译:用溶液结晶技术开发药物共晶体:杨梅素-脯氨酸共晶体的制备,表征和评估

获取原文
获取原文并翻译 | 示例
           

摘要

Myricetin shows low oral bioavailability (<10%) in rats due to poor aqueous solubility, although it has demonstrated various pharmacological activities such as those related to anticancer, anti-diabetes, and hepatic protection. To overcome this issue, in this study, pharmaceutical cocrystals were designed to efficiently deliver myricetin by oral administration. A 1:2 stoichiometric cocrystal of myricetin with proline was prepared successfully by solution crystallization based on the ternary phase diagram (TPD) principle, and it is presented as a new sphericity-like crystalline phase characterized by differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), and scanning electron microscopy (SEM). The formation of myricetin-proline cocrystals was a spontaneous and exothermic process, probably due to the supramolecular interactions between themselves, which were determined by Fourier transform infrared spectroscopy (FT-IR). Consequently, the dissolution efficiency of myricetin from cocrystals was increased 7.69-fold compared with that of coarse myricetin, and the oral bioavailability of myricetin cocrystals in rats was enhanced by approximately 3.03 times compared with that of pure myricetin. The present study provides useful information for the potential application of cocrystal technology for water-insoluble drugs, especially flavonoid compounds.(C) 2016 Elsevier B.V. All rights reserved.
机译:杨梅素由于不良的水溶性而在大鼠中显示出较低的口服生物利用度(<10%),尽管它已显示出各种药理活性,例如与抗癌,抗糖尿病和肝保护有关的药理活性。为了克服这个问题,在这项研究中,药物共晶体被设计为通过口服有效地递送杨梅素。根据三元相图(TPD)原理,通过溶液结晶法成功制备了杨梅素与脯氨酸的化学计量比为1:2的共晶,并以差示扫描量热法(DSC)表征为粉末状X球形新结晶相射线衍射(PXRD)和扫描电子显微镜(SEM)。杨梅素-脯氨酸共晶体的形成是自发的并且放热的过程,这可能是由于它们之间的超分子相互作用,这是通过傅立叶变换红外光谱法(FT-IR)确定的。因此,与粗制杨梅素相比,杨梅素在共晶体中的溶解效率提高了7.69倍,与纯杨梅素相比,在大鼠中口服杨梅素共晶体的生物利用度提高了约3.03倍。本研究为共晶体技术在水不溶性药物(尤其是类黄酮化合物)中的潜在应用提供了有用的信息。(C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号